Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

R(+)XK469

The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	XK469
Chemical structure:	2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}-, (+ )-(R)-

R(+)XK469

Search NCI's Drug Dictionary